MedPath

Ketoconazole

Generic Name
Ketoconazole
Brand Names
Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
Drug Type
Small Molecule
Chemical Formula
C26H28Cl2N4O4
CAS Number
65277-42-1
Unique Ingredient Identifier
R9400W927I
Background

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, miconazole and clotrimazole, due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis. These effects combined with waning efficacy led to its eventual replacement by triazole agents, fluconazole, itraconazole, voriconazole, and posaconazole. Ketoconazole and its predecessor clotrimazole continue to be used in topical formulations.

Indication

Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.

Associated Conditions
Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection

Ketoconazole Contributes to Cryptorchidism Outcome Via Modulating Macrophage Trem2

Not Applicable
Recruiting
Conditions
Cryptorchidism
Interventions
First Posted Date
2024-08-19
Last Posted Date
2024-08-19
Lead Sponsor
Affiliated Hospital of Nantong University
Target Recruit Count
10
Registration Number
NCT06560086
Locations
🇨🇳

Affiliated hospital of nantong university, Nantong, Jiangsu, China

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

Phase 1
Completed
Conditions
Tinea Versicolor
Interventions
First Posted Date
2024-03-12
Last Posted Date
2024-03-12
Lead Sponsor
Taro Pharmaceuticals USA
Target Recruit Count
430
Registration Number
NCT06305637
Locations
🇺🇸

Taro, Hawthorne, New York, United States

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Phase 2
Recruiting
Conditions
Chronic Myeloid Leukemia, Chronic Phase
Interventions
First Posted Date
2022-12-06
Last Posted Date
2022-12-06
Lead Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Target Recruit Count
15
Registration Number
NCT05638763
Locations
🇲🇽

Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo Leon, Mexico

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

Early Phase 1
Terminated
Conditions
Glioblastoma Multiforme
Glioblastoma
Glioblastoma Multiforme of Brain
Glioblastoma Multiforme, Adult
Interventions
First Posted Date
2021-05-03
Last Posted Date
2025-03-13
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
1
Registration Number
NCT04869449
Locations
🇺🇸

Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States

Bioavailability of Levoketoconazole and Ketoconazole Tablets

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2019-12-26
Last Posted Date
2020-01-31
Lead Sponsor
Cortendo AB
Target Recruit Count
34
Registration Number
NCT04212000
Locations
🇺🇸

Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Early Phase 1
Active, not recruiting
Conditions
Sleep Restriction
Interventions
First Posted Date
2019-07-30
Last Posted Date
2023-11-07
Lead Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Target Recruit Count
5
Registration Number
NCT04037605
Locations
🇺🇸

Los Angeles Biomedical Research Institute, Torrance, California, United States

To Evaluate the Efficacy and Safety of Shampoo TD03 and TD07 in Scalp Diseases

Phase 3
Conditions
Scalp Dermatitis
Interventions
Other: TD03
Other: TD07
First Posted Date
2019-02-19
Last Posted Date
2022-10-26
Lead Sponsor
Sao Thai Duong Joint Stock Company
Target Recruit Count
366
Registration Number
NCT03845348
Locations
🇻🇳

Nationa Hospital of Dermatology, Hanoi, Vietnam

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

Phase 3
Completed
Conditions
Tinea Pedis
Interventions
First Posted Date
2019-01-31
Last Posted Date
2019-06-27
Lead Sponsor
Encube Ethicals Pvt. Ltd.
Target Recruit Count
831
Registration Number
NCT03824912
Locations
🇱🇨

FXM Research International, Castries, Saint Lucia

🇺🇸

International Dermatology Research, Inc., Miami, Florida, United States

🇺🇸

PEAK Research, LLC, Upper Saint Clair, Pennsylvania, United States

and more 5 locations

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

Early Phase 1
Terminated
Conditions
Glioma
Anatomic Stage IV Breast Cancer AJCC v8
Astrocytoma
Recurrent Glioma
Breast Carcinoma Metastatic in the Brain
Invasive Breast Carcinoma
Oligodendroglioma
Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Other: Best Practice
First Posted Date
2019-01-08
Last Posted Date
2024-08-15
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
15
Registration Number
NCT03796273
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Azoles Targeting Recurrent High Grade Gliomas

Early Phase 1
Not yet recruiting
Conditions
Brain Tumor, Recurrent
Cancer, Advanced
Glioma of Brain
Interventions
First Posted Date
2018-12-04
Last Posted Date
2024-03-08
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
30
Registration Number
NCT03763396
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath